Side effects of The Glow Blend Peptide (BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg) Human safety data for these peptides, especially in combination, is limited
Protocol integration: Continue standard pressure-lowering drops as prescribed
This medicine works by inhibiting cyclin dependent kinase 4 and 6, thus arrests the cancer cell cycle (cell growing process)
This is why thorough clinical trials are essential to evaluate the safety and efficacy of peptides before they are approved for human use
Pelletier JP, Fernandes JC, Brunet J, et al
Sobczak M, Saaga M, Storr MA, Fichna J (2014) Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives